Occult hepatitis B in kidney transplants recipients and donors from Western Mexico

Fernández-Galindo, David A.; Galván-Ramírez, María de la Luz; Andrade‐Sierra, Jorge; González-Espinoza, Eduardo; Evangelista-Carrillo, Luis Alberto; Mendoza-Cabrera, Salvador; Rodríguez-Pérez, Laura Rocío; Chiquete, Erwin; Armendáriz‐Borunda, Juan; Sánchez-Orozco, Laura V.

doi:10.1016/j.ijid.2019.10.023

Cited by 9 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of our seronegative OBI patients got a kidney transplant. Research by Mexicans also found that two out of 73 kidney recipients tested positive for HBV DNA after a three-month follow-up using high-sensitivity molecular methods [ 47 ]. Because of various epidemiological encounters, such as HD, transfusions, or even transplantation operations, renal transplant patients might become infected with HBV.…”

Section: Discussionmentioning

confidence: 99%

Occult Hepatitis B Infection among Hemodialysis Patients in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region

Eslami

Poortahmasebi

Sadeghi

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Regardless of the extensive screening for the detection of hepatitis B surface antigen (HBsAg), hemodialysis (HD) patients are still severely at the risk of occult hepatitis B virus infection (OBI), especially in developing countries. OBI is defined as the presence of HBV DNA with undetectable HBsAg in the liver and/or Serum. This study aims to determine the prevalence of OBI in HD patients in Tabriz Province, northwest of Iran, and inquire about the mutations in the detected HBsAg. In this cross-sectional descriptive study, ELISA method assessed serum and plasma samples of 118 HBsAg-negative patients undergoing HD treatment for HBV serological markers (HBsAg and Anti-HBc). Specific primers by nested polymerase chain reaction have been utilized to examine HBV DNA; also, direct sequencing of surface genes was carried out to characterize the viral genotypes and S gene mutations. Finally, followed by real-time PCR, the quantity of viral load in OBI-positive patients was determined. A total of 118 HD patients were included (63.6% were male and 36.4% female), with an overall mean age of 60.8 ± 12.8 years old. The prevalence of antihepatitis B core antibody (Anti-HBc) in the study population was 26.3% (31/118). Five patients (4.2%) were positive for HBV DNA and labeled OBI-positive; their plasma HBV-DNA load was less than 100 IU/ml. Following the phylogenetic analysis, the samples with OBI roughly belonged to genotype D, subtype ayw2 and only two had mutations within the S ’gene’s major hydrophilic region (MHR), including T123I, C124F, and P127T. This study reports the prevalence of OBI in the HBsAg-negative HD patients being at a rate of 4.2%, which can be a clinically vital consideration in this region. HBV serologic screening approaches need to be renewed to cover nucleic acid testing in the setting of hemodialysis and all the other high-risk groups associated with it (i.e., blood and organ donors).

show abstract

Section: Discussionmentioning

confidence: 99%

Occult Hepatitis B Infection among Hemodialysis Patients in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region

Eslami

Poortahmasebi

Sadeghi

et al. 2022

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

show abstract

“…Unlike HCV, HBV is a DNA virus, requiring a slightly different prophylaxis and control strategy, although it shares with HCV reliable detection, with serological marker and HBV-DNA testing to rule out occult infection: an exceptional occurrence which, in any case, is not infectious if serum DNA-HBV is undetectable [ 10 , 11 ]. The predominant differential factor of HBV is the availability of a vaccine for patients without current HBV infection (HBsAg and DNA-HBV-negative) or evidence of past infection (Anti-HBc and/or anti-HBs-positive).…”

Section: Hepatitis Virus In the Dialysis Populationmentioning

confidence: 99%

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

D’Marco

Puchades

Serra

et al. 2021

IJERPH

View full text Add to dashboard Cite

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with vaccination in the case of HBV and effective viral infection treatment for HCV. In this sense, a universal SARS-CoV-2 screening and contact precaution appear to be effective in preventing further transmission. Finally, regarding the progress, an international consensus with updated protocols that prioritize between old and new indicators would seem a reasonable tool to address these unexpended changes for the nephrology community.

show abstract

“…HBV infection is generally diagnosed when circulating hepatitis B virus surface antigen (HBsAg) is detected in the serum. 3 If the hepatitis B virus genome (HBV DNA) is detected in an HBsAg negative individual, the condition is referred to as occult hepatitis B infection (OBI). 4 The existence of OBI has been suggested since the early 1980s but has only been well identified in the last 10 years after the discovery of highly sensitive molecular biology techniques.…”

Section: Introductionmentioning

confidence: 99%

“…Fourth, it is often found in the immunocompromised such as kidney transplant donor. 2,3,5 Kidney transplantation is the first-choice treatment for end-stage renal disease (ESRD). 6 In transplant recipients, immunosuppressant drugs are used to improve the acceptance of the transplanted organ.…”

Section: Introductionmentioning

confidence: 99%

Occult Hepatitis B Infection in Kidney Transplant Patients

Paramita

Wibawa

2022

InaJGHE

View full text Add to dashboard Cite

Occult hepatitis B infection (OBI) is still a topic of debate worldwide. It is defined as the presence of hepatitis B virus (HBV) DNA in serum and/or liver from HBsAg-negative subjects. OBI may lead to the development of cirrhosis and hepatocellular carcinoma. It continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the introduction of oral therapy to treat HBV infection. HBV reactivation following organ transplantation can occur even in recipients with absent hepatitis B surface antigen and remains an important cause of morbidity and mortality. Concerning OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for both recipients of organ transplant and organ transplant donors especially in highly endemic areas of HBV. In the era of potent antivirals and with evolving knowledge, HBsAg (+) renal transplant candidates and recipients can be monitored and successfully treated. Kidney organs from HBsAg-negative and anti-HBc–positive donors should be considered for transplant candidates after weighing the risk-benefit ratio. All transplant candidates should receive HBV vaccination if they are not immune to facilitate receipt of an organ from a donor with anti-HBc seropositivity.

show abstract

Occult hepatitis B in kidney transplants recipients and donors from Western Mexico

Cited by 9 publications

References 38 publications

Occult Hepatitis B Infection among Hemodialysis Patients in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region

Occult Hepatitis B Infection among Hemodialysis Patients in Tabriz, Northwest of Iran: Prevalence and Mutations within the S Region

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

Occult Hepatitis B Infection in Kidney Transplant Patients

Contact Info

Product

Resources

About